NanoViricides Inc (NNVC) - Total Assets
Based on the latest financial reports, NanoViricides Inc (NNVC) holds total assets worth $8.36 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore how well can NanoViricides Inc service its debt to assess how comfortably operating cash covers total debt obligations.
NanoViricides Inc - Total Assets Trend (2006–2025)
This chart illustrates how NanoViricides Inc's total assets have evolved over time, based on quarterly financial data. See NNVC book value for net asset value and shareholders' equity analysis.
NanoViricides Inc - Asset Composition Analysis
Current Asset Composition (June 2025)
NanoViricides Inc's total assets of $8.36 Million consist of 18.9% current assets and 81.1% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 17.7% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $317.04K | 3.6% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2006–2025)
This chart illustrates how NanoViricides Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see NanoViricides Inc stock valuation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: NanoViricides Inc's current assets represent 18.9% of total assets in 2025, a decrease from 99.7% in 2006.
- Cash Position: Cash and equivalents constituted 17.7% of total assets in 2025, down from 91.9% in 2006.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 3.0% of total assets, an increase from 0.0% in 2006.
- Asset Diversification: The largest asset category is intangible assets at 3.6% of total assets.
NanoViricides Inc Competitors by Total Assets
Key competitors of NanoViricides Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Samsung Biologics Co Ltd
KO:207940
|
Korea | ₩18.34 Trillion |
|
Revolution Medicines Inc
NASDAQ:RVMD
|
USA | $2.25 Billion |
|
Abivax SA
PA:ABVX
|
France | €584.34 Million |
|
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821
|
China | CN¥20.70 Billion |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
|
USA | $1.53 Billion |
|
SOLENO THERAPEUT. DL-001
F:6XC
|
Germany | €563.83 Million |
|
SL Science Holding Limited Ordinary Shares
NASDAQ:SLBT
|
USA | $2.82 Million |
|
REMEGEN CO. LTD YC 1
F:REG
|
Germany | €7.25 Billion |
NanoViricides Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.06 | 2.48 | 54.49 |
| Quick Ratio | 1.06 | 2.48 | 54.49 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $70.18K | $2.41 Million | $18.15 Million |
NanoViricides Inc - Advanced Valuation Insights
This section examines the relationship between NanoViricides Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.01 |
| Latest Market Cap to Assets Ratio | 2.44 |
| Asset Growth Rate (YoY) | -31.2% |
| Total Assets | $8.82 Million |
| Market Capitalization | $21.57 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values NanoViricides Inc's assets at a significant premium (2.44x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: NanoViricides Inc's assets decreased by 31.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for NanoViricides Inc (2006–2025)
The table below shows the annual total assets of NanoViricides Inc from 2006 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | $8.82 Million | -31.18% |
| 2024-06-30 | $12.82 Million | -24.12% |
| 2023-06-30 | $16.90 Million | -28.07% |
| 2022-06-30 | $23.49 Million | -22.36% |
| 2021-06-30 | $30.26 Million | +26.54% |
| 2020-06-30 | $23.91 Million | +77.82% |
| 2019-06-30 | $13.45 Million | -27.49% |
| 2018-06-30 | $18.55 Million | -31.32% |
| 2017-06-30 | $27.00 Million | -26.29% |
| 2016-06-30 | $36.63 Million | -17.09% |
| 2015-06-30 | $44.19 Million | -0.86% |
| 2014-06-30 | $44.57 Million | +171.64% |
| 2013-06-30 | $16.41 Million | +4.98% |
| 2012-06-30 | $15.63 Million | +45.28% |
| 2011-06-30 | $10.76 Million | +19.64% |
| 2010-06-30 | $8.99 Million | +199.62% |
| 2009-06-30 | $3.00 Million | +104.41% |
| 2008-06-30 | $1.47 Million | +8.74% |
| 2007-06-30 | $1.35 Million | -50.53% |
| 2006-06-30 | $2.73 Million | -- |
About NanoViricides Inc
NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs to combat viral infections. The company's product portfolio includes NV-387 drug candidate developed for RSV and influenza indications and has completed phase 1a/1b human clinical trial for the evaluation of safety and tolerability; NV-387 as an active ingredient of drug product for… Read more